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ABSTRACT: 
Background: Adams-Oliver syndrome (AOS) is a rare disorder characterized by congenital limb 
defects and scalp cutis aplasia. In a proportion of cases, notable cardiac involvement is also apparent. 
Despite recent advances in the understanding of the genetic basis of AOS, for the majority of affected 
subjects the underlying molecular defect remains unresolved. This study aimed to identify novel 
genetic determinants of AOS. 
Methods and Results: Whole-exome sequencing was performed for 12 probands, each with a clinical 
diagnosis of AOS. Analyses led to the identification of novel heterozygous truncating NOTCH1 
mutations (c.1649dupA and c.6049_6050delTC) in two kindreds in which AOS was segregating as an 
autosomal dominant trait. Screening a cohort of 52 unrelated AOS subjects, we detected 8 additional 
unique NOTCH1 mutations, including three de novo amino-acid substitutions, all within the ligand-
binding domain. Congenital heart anomalies were noted in 47% (8/17) of NOTCH1-positive probands 
and affected family members. In leucocyte-derived RNA from subjects harboring NOTCH1 
extracellular domain mutations, we observed significant reduction of NOTCH1 expression, suggesting 
instability and degradation of mutant mRNA transcripts by the cellular machinery. Transient 
transfection of mutagenized NOTCH1 missense constructs also revealed significant reduction in gene 
expression. Mutant NOTCH1 expression was associated with down-regulation of the Notch target 
genes HEY1 and HES1, indicating that NOTCH1-related AOS arises through dysregulation of the 
Notch signaling pathway. 
Conclusions: These findings highlight a key role for NOTCH1 across a range of developmental 
anomalies that include cardiac defects, and implicate NOTCH1 haploinsufficiency as a likely 
molecular mechanism for this group of disorders. 
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Haploinsufficiency; NOTCH1 
 
-- 4 -- 
INTRODUCTION: 
Adams-Oliver syndrome (AOS; MIM 100300) is a rare developmental disorder, characterized by a 
range of abnormalities that include cranial aplasia cutis congenita (ACC) and terminal transverse limb 
defects (TTLD).1,2 The spectrum of defects observed implies dysregulation of multiple developmental 
pathways. Congenital heart defects (CHDs) have been reported in conjunction with AOS in up to 20% 
of cases and, when present, represent a serious mortality risk.3,4 Cardiac defects are also commonly 
associated with systemic structural vascular abnormalities, of which cutis marmorata telangiectatica 
congenita (CMTC) is the most frequently described.5 AOS primarily segregates as an autosomal 
dominant trait with variable phenotypic expression. A small number of kindreds are consistent with 
autosomal recessive disease gene transmission. In addition, sporadic cases with comparable clinical 
features indicate the occurrence of de novo mutations in causative disease genes. 
 The molecular genetic basis of AOS appears heterogeneous and, to date, defects within five 
genes have been reported, providing limited insight as to the molecular mechanisms underlying these 
important aspects of early development. Mutations of the ARHGAP31 and DOCK6 genes underlie a 
proportion of AOS cases displaying autosomal dominant and recessive inheritance, respectively.6,7 
Both ARHGAP31 and DOCK6 regulate the activity of the Rho GTPases Cdc42 and Rac1, which 
cycle between active, GTP-bound and inactive, GDP-bound states through the opposing modes of 
action of guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs). We 
have previously demonstrated that ARHGAP31 mutations cause AOS through a gain-of-function 
mechanism, which leads to an accumulation of inactive GTPase, disrupting actin cytoskeletal 
dynamics.6 Mutations in DOCK6 result in a more severe, multi-systemic phenotype due to a 
homozygous loss of GEF function.7 
More recently, the Notch signaling pathway has been implicated in AOS pathogenesis by the 
discovery of heterozygous alterations in the RBPJ gene, encoding the major transcription factor for 
Notch.8 Missense mutations within the DNA-binding domain of RBPJ result in impaired binding 
ability of the transcription factor to the HES1 promoter, likely disrupting the regulation of Notch 
target genes downstream.8 Moreover, two independent studies have identified homozygous mutations 
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of EOGT, encoding an EGF domain-specific enzyme demonstrated as critical in the glycosylation of 
Notch1 in mammalian cells.9,10 Most recently, a report by Stittrich et al. identified mutations of the 
NOTCH1 gene in a proportion of an AOS cohort.11 
These studies have provided some important insights into the molecular processes key to the 
development of AOS. However, despite congenital heart anomalies affecting approximately 1 in 5 
subjects with AOS, the ARHGAP31- and RBPJ-positive pedigrees reported in the literature have a 
notable lack of cardiovascular involvement.6,8,12 Although the majority of these mutation carriers may 
not have been assessed by cardiac imaging, these data implicate distinct regulatory systems in the 
pathogenesis of autosomal dominant AOS with congenital heart defects. We designed an exome-wide 
based study, to further define the genetic mechanisms relevant to the pathogenesis of AOS. Through 
this work, we identified novel heterozygous mutations of NOTCH1, providing independent 
verification of a critical role for this gene as a common cause of AOS in both autosomal dominant and 
sporadic cases. We have further used gene expression studies to examine the impact of NOTCH1 
mutation on downstream signaling and demonstrated a pathogenic effect in RNA extracted from AOS 
subjects harboring NOTCH1 defects. These cases display a striking genotype-phenotype correlation 
with a high prevalence of cardiac and vascular anomalies, highlighting the importance of Notch 
signaling in cardiovascular development and demonstrating a novel role for NOTCH1 in multiple 
developmental processes that include scalp and limb formation. 
 
METHODS: 
Patient cohorts 
Exome sequencing was performed for 12 unrelated probands, diagnosed with autosomal dominant 
AOS and negative for ARHGAP31 and RBPJ mutations. Criteria for diagnosis were according to the 
guidelines by Snape et al.5 Subsequent mutation screening of the NOTCH1 coding regions comprised 
a cohort of 52 additional individuals with a diagnosis of AOS (n=11 autosomal dominant, n=41 
isolated cases with no known family history). Cardiac clinical evaluation and echocardiography of 
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NOTCH1-positive patients and family members was conducted at specialist cardiology centers (UK, 
Germany, Italy, France) following referral by the respective consultant clinical geneticist. The study 
complies with the Declaration of Helsinki and informed written consent was obtained from all 
participants before taking part. The research protocol was approved by the local ethics committees 
(NRES Committee London (Bromley), UK and the Ethics Board of the Medical Faculty of the 
University of Erlangen, Germany). Patient samples were collected as either saliva (Oragene DNA 
collection kit, DNA Genotek) or blood, and genomic DNA was extracted according to standard 
protocols. 
 
Exome sequencing and mutation detection 
Exome libraries were generated with the SureSelect Human All Exon Target Enrichment kit (Agilent 
Technologies) using genomic DNA extracted from peripheral blood. Paired-end sequence reads were 
generated on an Illumina HiSeq 2000. Read alignment to the reference genome (hg19) and variant 
calling were performed as described previously,6 with variant annotation completed using the 
ANNOVAR software.13 Sequence variants were compared against publicly available databases 
(HapMap, 1000 Genomes Project, dbSNP, the NHLBI Exome Sequencing Project (ESP) Exome 
Variant Server, and an in-house repository of 400 exomes) to assess their novelty. Candidate genes 
were prioritized on the basis of novel truncating mutations (frameshift, nonsense, splice-site) in two or 
more independent probands. Of these, NOTCH1 was taken forward for further study due to 
compelling biological relevance to AOS pathogenesis. Validation of variant segregation and mutation 
screening of all NOTCH1 coding regions and intron-exon boundaries was performed by direct DNA 
sequencing using BigDye Terminator v3.1 chemistry on an ABI3730xl (Applied Biosystems). 
 
Mutagenesis and cell culture 
Wild-type NOTCH1 cDNA in pFN1A (Kazusa DNA Research Institute)14 was purchased from 
Promega. Identified AOS missense variants were introduced by site-directed mutagenesis using the 
QuikChange II XL kit (Agilent Technologies). Primer details are available on request. Cells were 
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maintained at 37°C in a humidified incubator with 5% CO2. Human endometrioid cancer (HeLa) cells 
were cultured in Dulbecco’s modified Eagle’s medium (DMEM) with Glutamax (Gibco Life 
Technologies), supplemented with 10% fetal bovine serum. HeLa cells were seeded in 100 mm dishes 
and grown to 80% confluence. Transient transfection was performed using FuGene HD transfection 
reagent (Promega) and transfected cells were incubated for 48 hours before harvesting for RNA 
extraction. 
 
Gene-expression analysis 
Total RNA was extracted from 2.5 ml of peripheral blood from NOTCH1-positive patients and a 26 
year old clinically unaffected female control using the PAXgene Blood RNA System (PreAnalytiX), 
following the manufacturer’s guidelines. For mutagenized constructs, RNA was extracted from 
transfected cells with the RNeasy Mini kit (Qiagen), according to the manufacturer’s instructions. 500 
ng of RNA was used for first strand cDNA synthesis with the High Capacity cDNA Reverse 
Transcription kit (Applied Biosystems). Quantitative real-time PCR was performed on a StepOnePlus 
real-time PCR machine (Applied Biosystems) using double-dye Taqman-style detection chemistry 
with the PrimerDesign 2x Precision Mastermix and custom-designed probe sets for NOTCH1, HEY1 
and HES1 mRNAs (PrimerDesign). GAPDH and ACTB house-keeping genes were used for 
normalization in mRNA relative quantifications using SDS v2.2 software. Gene of interest expression 
levels for patient and mutagenized samples were calculated by the 2–ΔΔCt method relative to the wild-
type baseline. Statistical analysis of real-time data was performed using a Mann-Whitney test to 
generate two-tailed p values (VassarStats software). 
 
RESULTS: 
Clinical features of NOTCH1 positive families 
The proband of family 1 (1-II:1) displayed cutis aplasia and marked TTLD at birth. The sibling 1-II:2 
was also born with a severe cutaneous and bony scalp defect, with TTLD affecting both feet. On 
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examination, the obligate carrier mother (1-I:3) exhibited no scalp or limb defects, but was found to 
have an unexplained heart murmur. Subject 1-I:1 had died at 5 months due to a congenital heart 
defect, but no further details were available. Patient 1-II:4 presented with syndactyly of the left hand 
and both feet, and CMTC on the abdomen and legs. Echocardiography revealed mild aortic stenosis 
and mild aortic regurgitation. Similar digit abnormalities and scalp ACC were displayed by subject 1-
III:1. Although 1-III:2 appeared clinically normal on examination, sonography of the heart also 
revealed mild aortic regurgitation (Table 1).  
Family 2 has been previously described by Dallapiccola et al.15 The proband (2-II:1) and his 
mother both exhibited ACC of the midline region of the scalp and cardiac investigation by 
ultrasonography identified coarctation of the aorta in both individuals. The mother (2-I:2) also had a 
vascular anomaly consisting of duplication of the right femoral artery. Surgical intervention to repair 
the aortic coarctation and femoral artery duplication were conducted at 14 and 17 years of age, 
respectively. The cardiac defect in subject 2-II:1 resembled the so-called ‘Shone’s complex’, an 
anatomic variant consisting of multiple levels of left-sided obstructive CHDs,3,18 including aortic 
coarctation, bicuspid aortic valve, and parachute non-stenotic mitral valve with mild regurgitation. 
Coarctectomy was performed at 5 months of age. 
Patient 3-III:1 was born with a large area of scalp ACC with an underlying calvarial defect and 
shortened distal phalanges of the toes (Figure 1). A recent echocardiography detected no obvious 
abnormality. The obligate carrier father (3-II:2) was clinically normal and cardiology examination 
was negative for cardiac defects. The relative 3-II:3 was considered to be affected with minor terminal 
hypoplasia of the phalanges of some toes but no cardiac anomaly was detected on sonography. 
The proband of family 4 (4-II:1) presented with scalp ACC of the posterior parietal region and 
brachydactyly of both hands. Cardiovascular abnormalities included coarctation of the aorta, valvular 
aortic stenosis, parachute mitral valve with valvular insufficiency, and a subaortic membranous 
ventricular septal defect (VSD), also indicative of Shone’s complex. Aortic coarctation was operated 
at 15 days of life; aortic valvulotomy and intervention for VSD were performed at 9 years of age. 
Aortic valve substitution surgery was completed at 23 years old. Echocardiography in the mother (4-
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I:2) revealed valvular aortic stenosis with thick fibrotic semilunar valves, moderate aortic valve 
insufficiency, and mild to moderate left ventricular hypertrophy (Table 1). 
Specific clinical features of sporadic cases 5–11 are summarized in Table 1. Representative 
images of the limb and scalp defects observed across our AOS cohort are shown in Figure 1. 
 
Identification of novel NOTCH1 variants 
The analysis of exome profiles of affected male probands from families 1 and 2 identified novel 
heterozygous variants (c.1649dupA; p.Y550* and c.6049_6050delTC; p.S2017Tfs*9) in the NOTCH1 
gene (NM_017617.3). Both mutations are predicted to result in premature stop codons of the mRNA 
transcript. Examination of available members of family 1 confirmed segregation of the c.1649dupA 
mutation with the phenotype (Figure 2). Unfortunately, DNA was not available from the affected 
mother of proband 2-II:1 for segregation analysis of the c.6049_6050delTC variant. 
Subsequent mutation screening of the NOTCH1 coding regions was performed in an extended 
replication cohort of 52 individuals with a clear clinical diagnosis of AOS. Novel NOTCH1 
heterozygous variants were identified in 9 additional subjects. Taken together with the exome data, 
we report a total of ten distinct heterozygous mutations in the NOTCH1 gene, one of which 
(c.1343G>A; p.R448Q) is recurrent, in 4 autosomal dominant families and 7 apparently sporadic 
cases with no known family history (Figure 2; Table I in the Data Supplement). All variants were 
confirmed by independent Sanger sequencing and absent from public variant databases. In families, 
segregation of the observed variant was consistent with the disease phenotype where DNA from 
multiple family members was available (Figure 2). In AOS mutation carriers with no family history of 
AOS or isolated cardiovascular disease, the sequencing of available parental DNA demonstrated that 
three mutations occurred de novo, namely c.1343G>A (p.R448Q) in proband 5-II:1, c.1345T>C 
(p.C449R) in proband 6-II:1 and c.1367G>A (p.C456Y) in proband 10-II:1. In Family 3, two 
unaffected paternal uncles and two clinically normal siblings of the proband 3-III:1 were negative for 
the c.4120T>C (p.C1374R) mutation (data not shown). However, the unaffected obligate carrier 
father (3-II:2) was confirmed to carry the mutation. Similarly, the unaffected mother of subject 7-II:1 
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was found to harbor the c.1220C>G (p.P407R) variant. Cardiovascular assessment of 3-II:2 and 7-I:2 
by echocardiography detected no underlying cardiac abnormality, confirming that these mutation 
carriers are phenotypically normal and demonstrating incomplete penetrance for mutations in this 
gene. 
 
NOTCH1 missense mutations are located within critical functional domains 
Five of the six missense mutations identified in this study are predicted to be pathogenic by 
MutationTaster2,19 PolyPhen-2,20 and/or SIFT prediction software21 (Table II in the Data 
Supplement). The affected amino acids are located across the length of the receptor, in the main 
situated within the extracellular EGF-repeat domain. Specifically, four mutations (p.P407R, p.R448Q, 
p.C449R and p.C456Y) occur in or adjacent to the ligand-binding domain, specified by EGF repeats 
11-13 (Figure 3A, Figure 4). The majority are strongly conserved across species and lie within highly 
conserved domains of the protein (Figure 3B). Further, three amino acid substitutions (p.C449R, 
p.C456Y and p.C1374R) affect cysteine residues, which are likely to disrupt disulfide bonds that are 
critical for the structure of EGF-like domains (Figure 4). By contrast, the p.A1740S mutation is 
located within the transmembrane domain and, while conserved across mammalian species, is not 
conserved in other vertebrate species and has a less clear impact upon the structural integrity of the 
receptor so remains a variant of unknown significance (Figure 3). 
 
NOTCH1 haploinsufficiency is implicated in AOS pathogenesis 
To assess the level of mutant mRNA transcripts, we conducted quantitative real-time PCR studies 
using RNA extracted from peripheral blood of three patients harboring NOTCH1 mutation 
(c.1343G>A and c.1649dupA (2 cases)). NOTCH1 transcript levels were significantly reduced by 
comparison to an unaffected control individual, demonstrating approximately 50% expression in all 
samples tested (Figure 5A). Whilst institutional ethical constraints precluded detailed cardiac 
evaluation of the control subject, it was made clear by personal testimony that there was no family 
history of developmental abnormalities relating to AOS-CHD. We additionally performed transient 
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transfection of mutagenized NOTCH1 constructs to examine the functional impact of missense 
mutations for which patient RNA was not available. Real-time PCR of RNA extracted from 
transfected cells also showed a significant decrease of NOTCH1 expression when compared to cells 
transfected with a full-length wild-type construct and provided independent verification of NOTCH1 
down-regulation for the c.1343G>A mutation (Figure I in the Data Supplement). 
 To further interrogate the effect of NOTCH1 mutations on downstream signaling factors, we 
next performed gene expression studies to quantify the levels of HEY1 and HES1 transcript in patient-
derived RNA samples. Subjects harboring the c.1649dupA frameshift mutation exhibited a 
particularly marked reduction of HEY1 transcript levels by comparison to wild-type control 
(p=0.0004). By contrast, down-regulation of HEY1 expression was less profound for the c.1343G>A 
missense mutation (Figure 5B). In addition, HES1 mRNA levels were reduced in the c.1649dupA 
patients (p=0.0004); however, no significant deviation to the wild-type control was observed in the 
c.1343G>A sample (Figure 5C).  
 
DISCUSSION: 
Molecular genetic studies of AOS have successfully provided vital insights into the pathways relevant 
to the pathogenesis of this serious disorder of morphogenesis, through the identification of multiple 
causative genes. Yet, there remains substantial unexplained locus heterogeneity with the underlying 
molecular genetic determinants still uncharacterized for the majority of cases. This degree of locus 
heterogeneity is uncommon for a rare disorder and suggests that AOS may represent a cluster of 
phenotypes with a related etiology, analogous to the RASopathies or ciliopathies.23,24  
Herein, we report 10 novel germline NOTCH1 mutations in a patient cohort with autosomal 
dominant and sporadic forms of AOS. By comparison to AOS cases reported in the literature (13-
20%),3-5,25,26 a significantly higher proportion of probands (5/11; 45%) presented with a congenital 
heart abnormality (Table 1). Similarly, cardiovascular anomalies were identified in 47% (8/17) of all 
affected variant carriers, thereby indicating that NOTCH1 variants may represent a distinct subtype of 
-- 12 -- 
AOS associated with cardiac malformations. A number of vascular complications, including CMTC 
and portal vein abnormalities, were additionally observed in NOTCH1-positive cases. Importantly, 
two of the probands in this study and two related mutation carriers have not undergone 
echocardiographic assessment; therefore we are unable to define the exact proportion of NOTCH1-
positive cases with cardiovascular defects. In contrast to other gene reports, these patients 
predominantly demonstrate ACC with mild TTLD, affecting only terminal phalanges with nail 
hypoplasia (Figure 1). This study is further corroborated by a recent report of distinct NOTCH1 
mutations in 5 kindreds with AOS and cardiac spectrum defects.11 
Emerging evidence is accumulating to implicate defects of the Notch signaling pathway in the 
pathogenesis of AOS. The Notch family of single-pass transmembrane receptors is well documented 
as playing a vital role in multiple cellular processes during embryogenesis and Notch pathway 
members have an established role in development of the cardiovascular system.27 Mutations in a 
subset of Notch components have been shown to underlie CHDs in both mice and humans but in 
exclusion of limb and scalp developmental abnormalities. For example, variants in the JAG1 gene, 
encoding a Notch ligand, underlie the majority of cases of Alagille syndrome28 whilst endothelial-
specific deletion of Jag1 in the mouse leads to embryonic lethality and cardiovascular defects.29 
NOTCH2 mutations account for a proportion of Alagille syndrome cases;30 however, distinct 
truncating variants in the terminal exon of NOTCH2 also lead to the osteolytic developmental disorder 
Hajdu-Cheney syndrome, indicating pleiotropic effects analogous to the NOTCH1 receptor.31,32 Of 
interest, mice homozygous for a targeted Jag2 deletion die perinatally due to craniofacial 
abnormalities and syndactyly of the fore- and hindlimbs, consistent features of the AOS spectrum.33 
Furthermore, both Notch1 and Notch2 play key roles during mouse limb development in the 
regulation of apoptosis, a process mediated by Notch signaling through Jag2 in the apical ectodermal 
ridge,34,35 and the positive regulation of vascular growth through the promotion of angiogenesis and 
osteogenesis in bone.36 Despite numerous studies in lower organisms, the function of NOTCH1 
during human fetal development remains to be fully elucidated. 
In mammalian cells, canonical signaling through the Notch family (Notch1-4) is stimulated by 
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ligand binding at the cell surface, which leads to proteolytic cleavage of the Notch intracellular 
domain (NICD), allowing for the formation of a transcriptional complex with RBPJ and co-activators 
(Figure 6).37 RBPJ is known to regulate the expression of the basic helix-loop-helix (bHLH) 
transcription factors HES1 and HEY1, both of which are related to the Drosophila hairy and enhancer 
of split 1 gene. The stimulation of HES1 and HEY1 gene expression is therefore a direct readout of 
Notch signaling activation. 
In this study, we report predicted protein truncating mutations (4/10) most likely to be subject 
to nonsense-mediated decay. The N-terminal ligand-binding domain of NOTCH1 consists of a series 
of 36 EGF-like repeats. The majority (5/6) of the missense mutations identified in this study affect 
residues located within EGF domains of the receptor. These individual domains are characterized by a 
core β-pleated sheet, three disulfide bonds along with a series of variable loops.38 Within this region, 
EGF repeats 11-13 have been shown to be implicated with chelating Ca2+ which is essential for the 
maintenance of NOTCH1 function.38,39 Three of the identified amino acid substitutions resulting in 
AOS (p.R448Q, p.C449R and p.C456Y) lie within EGF11 and potentially perturb function by 
disrupting the tertiary structure and affecting Ca2+ binding and/or ligand interaction. The X-ray 
structure of this region of wild-type NOTCH1 indicates that the side chains of Arg448 and Glu424 
interact electrostatically (Figure 4),22 thereby it is anticipated that the p.R448Q mutant is unstable. 
Similarly, the p.C449R and p.C456Y mutations will likely abolish the disulfide bonds between 
Cys440 and Cys449, and between Cys456 and Cys467, respectively, thereby disrupting the stability 
of the adjacent Ca2+ coordinated by the side chains Asp469, Glu455 and Asp452 (Figure 4). Whilst 
the 3-dimensional structure of the EGF35 region has not been experimentally resolved, it is 
anticipated that a similar effect would be seen with the Cys1374 mutation. Taken together, these 
observations imply that the majority of missense mutations have a substantial effect on the structural 
integrity vital to NOTCH1 activity. Determining the functional impact of the transmembrane domain 
mutation p.A1740S is outside the scope of this study and is therefore of unknown significance. 
The 36 EGF-like repeats can be modified by the addition of an O-glucose sugar between the 
first and second conserved cysteines, and an O-fucose between the second and third cysteines, which 
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is essential for normal Notch function.40 Similarly, the target motif C5XXGXS/TGXXC6, located 
between the fifth and sixth conserved cysteines has been shown to be recognized by EOGT in both 
Drosophila and mouse.41 EOGT functions as an O-linked N-acetylglucosamine (GlcNAc) transferase, 
which catalyses the addition of an O-GlcNAc moiety.42 Although EOGT has not yet been formally 
demonstrated to target human Notch, it is notable that 4 of the 5 EGF-domain specific missense 
mutations identified here are located within this target motif, suggestive of a convergence of pathways 
previously implicated in the development of AOS (Figure 3B).  
To examine the effect of identified mutations on Notch signaling, we have performed gene 
expression studies and demonstrated that NOTCH1 expression is down-regulated in AOS subjects 
harboring NOTCH1 mutation in vivo, by comparison to a single healthy control female, aged 26 years. 
While it is not uncommon to use a single control in real-time PCR studies, we acknowledge that these 
findings might have been strengthened by employing additional controls as part of the experimental 
design. The data generated are corroborated by transient transfection studies of mutant constructs and, 
together, support the prediction of transcript loss by nonsense-mediated decay or, in the case of 
missense mutations, potential perturbation of mRNA stability.43 This observation is underpinned by a 
reduction of HEY1 and, to a lesser extent, HES1 transcript levels. Of interest, perturbation of both 
HEY1 and HES1 expression vary between the mutations tested, indicating allele-specific effects on 
downstream signaling. These data, whilst preliminary due in part to limited patient sample 
availability, suggest that down-regulation of HEY1 is a common mechanism in AOS. HEY1 is known 
to have a prominent role in cardiovascular development, with Hey1/Hey2 double-knockout mice 
exhibiting defects of vasculogenesis and remodeling, particularly in the head region.44 Moreover, 
these results are compatible with the hypothesis that dysregulated Notch signaling caused by 
identified mutations is mediated via the transcription factor RBPJ, a known causal factor in AOS 
pathogenesis. Taken together, these data offer support for loss-of-function or haploinsufficiency of 
NOTCH1 as an important factor in AOS pathogenesis, and provide a compelling genotype-phenotype 
correlation between NOTCH1 mutation and AOS subjects with cardiac anomalies, which warrants 
further epidemiological investigation. As the overall study group herein has not been intensively 
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examined for cardiac complications, these latter conclusions are at present indicative and will benefit 
from existing and future international collaboration. 
 This report establishes NOTCH1 mutation as the primary cause of AOS, accounting for 17% of 
cases in our cohort, and an important genetic factor in AOS with associated cardiovascular 
complications. Functional studies have indicated links to related genes associated with this condition, 
which together emphasize the central importance of the Notch signaling cascade in a series of key 
developmental systems in human embryogenesis. 
 
ACKNOWLEDGMENTS: 
The authors would like to express their thanks to the patients and families for participating in this 
study and to the various clinicians involved in the European AOS Consortium, for sharing additional 
patient samples that have not been reported here. The authors acknowledge use of Biomedical 
Research Centre (BRC) Core Facilities provided by the financial support from the Department of 
Health via the National Institute for Health Research (NIHR) comprehensive BRC award to Guy’s 
and St Thomas’ NHS Foundation Trust in partnership with King’s College London and King’s 
College Hospital NHS Foundation Trust. 
 
FUNDING SOURCES: 
This work was supported by the British Heart Foundation [RG/08/006/25302 to R.C.T.], the German 
Research Foundation [DFG; ZE 524/2-3 to M.Z.] and a Wellcome Trust Strategic Award 
[102627/Z/13/Z to R.C.T.]. A.S.V.K. is the recipient of a PrimerDesign Gold level student 
sponsorship. E.J.T. is a Royal Society University Research Fellow. R.C.T. held a Senior Investigator 
Award from the NIHR. 
 
DISCLOSURES: 
No conflicts of interest declared. 
-- 16 -- 
REFERENCES: 
1. Adams FH, Oliver CP. Hereditary deformities in man due to arrested development. J Hered. 
1945;36:3-7. 
2. Martínez-Frías ML, Arroyo Carrera I, Muñoz-Delgado NJ, Nieto Conde C, Rodríguez-Pinilla 
E, Urioste Azcorra M, et al. [The Adams-Oliver syndrome in Spain: the epidemiological aspects]. An 
Esp Pediatr. 1996;45:57-61. 
3. Lin AE, Westgate MN, van der Velde ME, Lacro RV, Holmes LB. Adams-Oliver syndrome 
associated with cardiovascular malformations. Clin Dysmorphol. 1998;7:235-241. 
4. Digilio MC, Marino B, Dallapiccola B. Autosomal dominant inheritance of aplasia cutis 
congenita and congenital heart defect: a possible link to the Adams-Oliver syndrome. Am J Med 
Genet A. 2008;146A:2842-2844. 
5. Snape KM, Ruddy D, Zenker M, Wuyts W, Whiteford M, Johnson D, et al. The spectra of 
clinical phenotypes in aplasia cutis congenita and terminal transverse limb defects. Am J Med Genet. 
2009;149A:1860-1881. 
6. Southgate L, Machado RD, Snape KM, Primeau M, Dafou D, Ruddy DM, et al. Gain-of-
function mutations of ARHGAP31, a Cdc42/Rac1 GTPase regulator, cause syndromic cutis aplasia 
and limb anomalies. Am J Hum Genet. 2011;88:574-585. 
7. Shaheen R, Faqeih E, Sunker A, Morsy H, Al-Sheddi T, Shamseldin HE, et al. Recessive 
mutations in DOCK6, encoding the guanidine nucleotide exchange factor DOCK6, lead to abnormal 
actin cytoskeleton organization and Adams-Oliver syndrome. Am J Hum Genet. 2011;89:328-333. 
8. Hassed SJ, Wiley GB, Wang S, Lee JY, Li S, Xu W, et al. RBPJ mutations identified in two 
families affected by Adams-Oliver syndrome. Am J Hum Genet. 2012;91:391-395. 
9. Shaheen R, Aglan M, Keppler-Noreuil K, Faqeih E, Ansari S, Horton K, et al. Mutations in 
EOGT confirm the genetic heterogeneity of autosomal-recessive Adams-Oliver syndrome. Am J Hum 
Genet. 2013;92:598-604. 
-- 17 -- 
10. Cohen I, Silberstein E, Perez Y, Landau D, Elbedour K, Langer Y, et al. Autosomal recessive 
Adams-Oliver syndrome caused by homozygous mutation in EOGT, encoding an EGF domain-
specific O-GlcNAc transferase. Eur J Hum Genet. 2014;22:374-378. 
11. Stittrich AB, Lehman A, Bodian DL, Ashworth J, Zong Z, Li H, et al. Mutations in NOTCH1 
cause Adams-Oliver syndrome. Am J Hum Genet. 2014;95:275-284. 
12. Isrie M, Wuyts W, Van Esch H, Devriendt K. Isolated terminal limb reduction defects: 
extending the clinical spectrum of Adams-Oliver syndrome and ARHGAP31 mutations. Am J Med 
Genet A. 2014;164A:1576-1579. 
13. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from 
high-throughput sequencing data. Nucleic Acids Res. 2010;38:e164. 
14. Nagase T, Yamakawa H, Tadokoro S, Nakajima D, Inoue S, Yamaguchi K, et al. Exploration 
of human ORFeome: high-throughput preparation of ORF clones and efficient characterization of 
their protein products. DNA Res. 2008;15:137-149. 
15. Dallapiccola B, Giannotti A, Marino B, Digilio C, Obregon G. Familial aplasia cutis congenita 
and coarctation of the aorta. Am J Med Genet. 1992;43:762-763. 
16. Girard M, Amiel J, Fabre M, Pariente D, Lyonnet S, Jacquemin E. Adams-Oliver syndrome and 
hepatoportal sclerosis: occasional association or common mechanism? Am J Med Genet A. 
2005;135:186-189. 
17. Franchi-Abella S, Fabre M, Mselati E, De Marsillac ME, Bayari M, Pariente D, et al. 
Obliterative portal venopathy: a study of 48 children. J Pediatr. 2014;165:190-193 e2. 
18. Shone JD, Sellers RD, Anderson RC, Adams P, Jr., Lillehei CW, Edwards JE. The 
developmental complex of "parachute mitral valve," supravalvular ring of left atrium, subaortic 
stenosis, and coarctation of aorta. Am J Cardiol. 1963;11:714-725. 
19. Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the 
deep-sequencing age. Nat Methods. 2014;11:361-362. 
20. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method 
and server for predicting damaging missense mutations. Nat Methods. 2010;7:248-249. 
-- 18 -- 
21. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on 
protein function using the SIFT algorithm. Nat Protoc. 2009;4:1073-1081. 
22. Cordle J, Johnson S, Tay JZ, Roversi P, Wilkin MB, de Madrid BH, et al. A conserved face of 
the Jagged/Serrate DSL domain is involved in Notch trans-activation and cis-inhibition. Nat Struct 
Mol Biol. 2008;15:849-857. 
23. Zenker M. Clinical manifestations of mutations in RAS and related intracellular signal 
transduction factors. Curr Opin Pediatr. 2011;23:443-451. 
24. Davis EE, Katsanis N. The ciliopathies: a transitional model into systems biology of human 
genetic disease. Curr Opin Genet Dev. 2012;22:290-303. 
25. Patel MS, Taylor GP, Bharya S, Al-Sanna'a N, Adatia I, Chitayat D, et al. Abnormal pericyte 
recruitment as a cause for pulmonary hypertension in Adams-Oliver syndrome. Am J Med Genet A. 
2004;129A:294-299. 
26. Algaze C, Esplin ED, Lowenthal A, Hudgins L, Tacy TA, Selamet Tierney ES. Expanding the 
phenotype of cardiovascular malformations in Adams-Oliver syndrome. Am J Med Genet A. 
2013;161A:1386-1389. 
27. High FA, Epstein JA. The multifaceted role of Notch in cardiac development and disease. Nat 
Rev Genet. 2008;9:49-61. 
28. Oda T, Elkahloun AG, Pike BL, Okajima K, Krantz ID, Genin A, et al. Mutations in the human 
Jagged1 gene are responsible for Alagille syndrome. Nat Genet. 1997;16:235-242. 
29. High FA, Lu MM, Pear WS, Loomes KM, Kaestner KH, Epstein JA. Endothelial expression of 
the Notch ligand Jagged1 is required for vascular smooth muscle development. Proc Natl Acad Sci U 
S A. 2008;105:1955-1959. 
30. McDaniell R, Warthen DM, Sanchez-Lara PA, Pai A, Krantz ID, Piccoli DA, Spinner NB. 
NOTCH2 mutations cause Alagille syndrome, a heterogeneous disorder of the notch signaling 
pathway. Am J Hum Genet. 2006;79:169-173. 
31. Isidor B, Lindenbaum P, Pichon O, Bezieau S, Dina C, Jacquemont S, et al. Truncating 
mutations in the last exon of NOTCH2 cause a rare skeletal disorder with osteoporosis. Nat Genet. 
2011;43:306-308. 
-- 19 -- 
32. Simpson MA, Irving MD, Asilmaz E, Gray MJ, Dafou D, Elmslie FV, et al. Mutations in 
NOTCH2 cause Hajdu-Cheney syndrome, a disorder of severe and progressive bone loss. Nat Genet. 
2011;43:303-305. 
33. Jiang R, Lan Y, Chapman HD, Shawber C, Norton CR, Serreze DV, et al. Defects in limb, 
craniofacial, and thymic development in Jagged2 mutant mice. Genes Dev. 1998;12:1046-1057. 
34. Francis JC, Radtke F, Logan MP. Notch1 signals through Jagged2 to regulate apoptosis in the 
apical ectodermal ridge of the developing limb bud. Dev Dyn. 2005;234:1006-1015. 
35. Pan Y, Liu Z, Shen J, Kopan R. Notch1 and 2 cooperate in limb ectoderm to receive an early 
Jagged2 signal regulating interdigital apoptosis. Dev Biol. 2005;286:472-482. 
36. Ramasamy SK, Kusumbe AP, Wang L, Adams RH. Endothelial Notch activity promotes 
angiogenesis and osteogenesis in bone. Nature. 2014;507:376-380. 
37. Gridley T. Notch signaling in vascular development and physiology. Development. 
2007;134:2709-2718. 
38. Hambleton S, Valeyev NV, Muranyi A, Knott V, Werner JM, McMichael AJ, et al. Structural 
and functional properties of the human notch-1 ligand binding region. Structure. 2004;12:2173-2183. 
39. de Celis JF, Barrio R, del Arco A, Garcia-Bellido A. Genetic and molecular characterization of 
a Notch mutation in its Delta- and Serrate-binding domain in Drosophila. Proc Natl Acad Sci U S A. 
1993;90:4037-4041. 
40. Lu L, Stanley P. Roles of O-fucose glycans in notch signaling revealed by mutant mice. 
Methods Enzymol. 2006;417:127-136. 
41. Alfaro JF, Gong CX, Monroe ME, Aldrich JT, Clauss TR, Purvine SO, et al. Tandem mass 
spectrometry identifies many mouse brain O-GlcNAcylated proteins including EGF domain-specific 
O-GlcNAc transferase targets. Proc Natl Acad Sci U S A. 2012;109:7280-7285. 
42. Sakaidani Y, Ichiyanagi N, Saito C, Nomura T, Ito M, Nishio Y, et al. O-linked-N-
acetylglucosamine modification of mammalian Notch receptors by an atypical O-GlcNAc transferase 
Eogt1. Biochem Biophys Res Commun. 2012;419:14-19. 
43. Cartegni L, Chew SL, Krainer AR. Listening to silence and understanding nonsense: exonic 
mutations that affect splicing. Nat Rev Genet. 2002;3:285-298. 
-- 20 -- 
44. Fischer A, Schumacher N, Maier M, Sendtner M, Gessler M. The Notch target genes Hey1 and 
Hey2 are required for embryonic vascular development. Genes Dev. 2004;18:901-911. 
 
 
 
-- 21 -- 
TABLE 1: Clinical characteristics of AOS affected subjects harboring NOTCH1 mutations 
Subject 
ID 
Country 
of origin 
Current 
age 
Gender Scalp 
ACC 
TTLD Cardiac and/or vascular 
features [age at diagnosis] 
Echocardiographic assessment [age 
at assessment] 
Other features [age at 
diagnosis] 
1-II:1* UK 29 yr male ++ + nd not assessed undefined heart murmur 
1-II:2 28 yr male ++ + nd not assessed undefined heart murmur 
1-II:4 35 yr female – ++ [34 yr]: AR; AS; CMTC on 
abdomen and legs 
[34 yr]: mild AS and AR (PV: 2.04 m/s, 
PG: 16.65 mmHg), mildly increased 
velocities through pulmonary valve 
(2.06 m/s) and descending aorta (2 m/s) 
– 
1-III:1 17 yr male + ++ nd not assessed – 
1-III:2 10 yr female – – [9 yr]: AR [9 yr]: mild AR (PV: 2.21 m/s, PG: 
19.54 mmHg), mildly increased 
velocities through pulmonary valve 
(1.91 m/s) and descending aorta (2.3 
m/s) 
– 
2-II:1* Italy 27 yr male + – [15 d]: BAV; CoA; PMV; 
[5 mo]: subclavian flap 
[15 d]: non-stenotic PMV with mild 
regurgitation 
Ref: Dallapiccola et al. 1992 
(Patient 2).15 
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coarctectomy 
3-II:3 Germany 35 yr male – + – [34 yr]: normal – 
3-III:1* 8 yr male ++ + – [7 yr]: normal – 
4-I:2 Italy 47 yr female – – AR; AS [47 yr]: thick fibrotic semilunar valves; 
moderate AR (PG: 34 mmHg, MG: 20 
mmHg); mild to moderate LVH 
long palpebral fissures 
4-II:1* 25 yr female + ++ [15 d]: AS; CoA; PMV; 
VSD 
[15 d]: subaortic membranous VSD; 
severe AS (PG: 80 mmHg, MG: 60 
mmHg); PMV with valvular 
insufficiency 
long palpebral fissures 
5-II:1* UK 10 yr male ++ – [1 d]: PA-VSD; [6 d]: right 
MBTS; [2 yr]: Rastelli 
correction 
[1 d]: PA, VSD Fallot type; [10 yr]: 
some narrowing of shunt, free 
pulmonary regurgitation 
[5 yr]: portal vein thrombosis; 
portal hypertension; T cell 
lymphopenia; complex 
learning disability; autism 
6-II:1* Russia deceased female ++ + [in utero]: truncus 
arteriosus communis type 
I; [1 d]: VSD 
[1 d]: membrane VSD, right-sided 
aortic bow descending on left-hand side 
– 
-- 23 -- 
7-II:1* Italy 8 yr male + + – [7 yr]: normal bilateral cryptorchidism; 
bilateral abdominal wall 
hernia; hypertelorism; 
downslanting palpebral fissures 
8-II:1* Italy 15 yr male + + [1 d]: CMTC [15 yr]: normal epilepsy; dyslexia 
9-II:1* Germany 33 yr female + ++ nd not assessed – 
10-II:1* France 16 yr female ++ ++ [3.5 yr]: ASD; surgically 
closed at 4 yr; 
arteriography: EHPVT, 
hepatopetal and 
hepatofugal collateral veins 
[3.5 yr]: ASD, suspected 
portopulmonary hypertension (mPAP: 
30 mmHg); [7 yr]: mPAP: 45 mmHg, 
PVR: 8.1 Wood U/m2, PWP: <15 
mmHg; [12 yr]: mPAP: 27 mmHg with 
Sildenafil treatment 
[3.5 yr]: HSM and portal 
hypertension with GI bleeding; 
OPV. Ref: Girard et al. 2005 
(Patient 1);16 Franchi-Abella et 
al. 2014.17  
11-II:1* Greece 19 yr male ++ ++ [6.5 yr]: arteriography: 
EPVO, large hepatofugal 
coronary vein, tiny 
hepatopetal cavernoma 
[6.5 yr]: normal; [14 yr]: normal [6.5 yr]: HSM and portal 
hypertension; OPV. Ref: 
Girard et al. 2005 (Patient 2);16 
Franchi-Abella et al. 2014.17 
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Key:  –, absent; +, present (for ACC: +, small defect (<5 cm); ++, large defect (>5 cm) with underlying osseous skull defect; for TTLD: +, feet or hands only; 
++, both feet and hands affected); ACC, aplasia cutis congenita; AR, aortic regurgitation; AS, aortic valve stenosis; ASD, atrial septal defect; BAV, bicuspid 
aortic valve; CMTC, cutis marmorata telangiectatica congenita; CoA, coarctation of the aorta; EPVO, extra-hepatic portal vein obstruction; EHPVT, extra-
hepatic portal vein thrombosis; GI, gastrointestinal; HSM, hepatosplenomegaly; LVH, left ventricular hypertrophy; MBTS, modified Blalock–Taussig shunt; 
MG: median gradient; mPAP, mean pulmonary arterial pressure (measured by right heart catheterization); nd, not determined; OPV, obliterative portal 
venopathy; PA, pulmonary atresia; PG, peak gradient; PMV, parachute mitral valve; PV, peak velocity; PVR, pulmonary vascular resistance; PWP, 
pulmonary wedge pressure; Ref:, reference of case report; TTLD, terminal transverse limb defects; VSD, ventral septal defect. Subject identifiers refer to the 
pedigree structures in Figure 1. The proband for each family is marked with an asterisk. 
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FIGURE LEGENDS: 
Figure 1. Clinical features of three representative AOS patients with NOTCH1 mutation. (left) 
Patient 3-III:1 at age 2.8 years: residual skin defect after multiple operations on a large area of scalp 
aplasia cutis congenita; minor hypoplasia of terminal phalanges of the toes; normal fingers. (middle) 
Patient 6-II:1 as a newborn: large scalp defect involving the underlying bone; hypoplasia of terminal 
phalanges of both feet. (right) Patient 8-II:1 at age 14.7 years: small area of alopecia marking a healed 
scalp defect; hypoplasia of terminal phalanges and nails of the left foot; normal fingers. 
 
Figure 2. Pedigree structures and sequence chromatograms of identified NOTCH1 mutations. 
Asterisks denote the families included in the exome sequencing discovery cohort. Probands are 
marked by the black arrows and asymptomatic carriers are indicated with black dots. For de novo 
mutations, paternity was confirmed by microsatellite analysis (data not shown). Key:  +, wild-type 
allele; –, mutant allele.  
 
Figure 3. Location and conservation of NOTCH1 mutations. (A) Schematic of the NOTCH1 
protein highlighting the critical functional domains. The AOS mutations identified in this study are 
arrayed below the schematic. Truncating mutations are marked in green type and orange depicts 
missense mutations. (B) Conservation of the 6 missense mutations across species. Conserved residues 
are highlighted in orange. The 4th, 5th and 6th conserved cysteines within the EGF domains are boxed. 
Accession numbers: H. sapiens: NP_060087.3; M. mulatta: AFH32544.1; C. lupus familiaris: 
XP_005625490.1 (predicted); M. musculus: NP_032740.3; G. gallus: NP_001025466.1; X. tropicalis: 
NP_001090757.1; D. rerio: NP_571377.2; T. rubripes: XP_003975158.1 (predicted); D. 
melanogaster: NP_476859.2. 
 
Figure 4. Ball and stick representation of the 3-dimensional structure of human NOTCH1 EGF 
repeats 11-13. The positions of the adjacent AOS mutations p.R448Q and p.C449R are highlighted 
by the solid red arrows. The p.C456Y mutation is similarly marked. The solid black arrows indicate 
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the disulfide bonds which would be abolished by the p.C449R and p.C456Y mutations, respectively. 
The side chains of the key Ca2+ ion coordinating residues (Asp452, Glu455 and Asp469) and Glu424 
are indicated. Water molecules have been removed for clarity. Figure produced from the crystal 
structure (PDB ID: 2VJ3)22 using the PyMOL Molecular Graphics System. 
 
Figure 5. Real-time PCR of NOTCH1-positive patient samples. Graphs show levels of gene 
expression for (A) NOTCH1, (B) HEY1 and (C) HES1. Relative quantification of mRNA transcripts 
are calculated relative to the WT baseline value (set at 1) and normalized to endogenous GAPDH and 
ACTB levels. Graphs represent the mean of three independent experiments with error bars indicating 
SEM. The brackets denote individuals with identical NOTCH1 mutations. Key: *p<0.001; †p<0.01 
 
Figure 6. Simplified schematic of the canonical Notch signaling pathway. (A) The EGF-repeat 
domain of Notch is known to be glycosylated by EOGT in mammalian cells. Activation of the Notch 
signaling cascade is initiated by the binding of one of five ligands through direct contact of adjacent 
cells. (B) Ligand activation leads to cleavage and release of NICD, which translocates to the nucleus 
to form an active transcriptional complex with RBPJ, mastermind (MAML) and transcriptional co-
activators (CoA). (C) In the absence of Notch activation, RBPJ complexes with co-repressor proteins 
(CoR) to repress transcription of downstream genes. Mutations in EOGT and RBPJ have previously 
been identified in AOS. 
 
-- 27 -- 
 
FIGURE 1: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-- 28 -- 
 
FIGURE 2: 
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FIGURE 4: 
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FIGURE 5: 
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FIGURE 6: 
 
 
 
SUPPLEMENTAL MATERIAL 
 
SUPPLEMENTAL TABLE I.  Summary of identified NOTCH1 variants 
Exon Coding variant Protein variant Variant type Protein domain 
7 c.1220C>G p.P407R Missense EGF 10 
8 c.1343G>A p.R448Q Missense EGF 11 
8 c.1345T>C p.C449R Missense EGF 11 
8 c.1367G>A p.C456Y Missense EGF 11 
10 c.1649dupA p.Y550* Frameshift EGF 14 
25 c.4120T>C p.C1374R Missense EGF 35 
26 c.4663G>T p.E1555* Nonsense LNR 3 
26 c.4739dupT p.M1580Ifs*30 Frameshift - 
28 c.5218G>T p.A1740S Missense TM 
32 c.6049_6050delTC p.S2017Tfs*9 Frameshift ANK 4 
Key to abbreviations: EGF, epidermal growth factor-like repeat domain; LNR, Lin-12 NOTCH repeat domain; 
TM, transmembrane domain; ANK, ankyrin repeat domain. 
 
 
SUPPLEMENTAL TABLE II.  Predicted pathogenicity of identified NOTCH1 variants 
Variant MutationTaster2 PolyPhen-2 SIFT Protein 
p.P407R Disease causing (prob: 0.999) Probably damaging (0.968) Tolerated (0.51) 
p.R448Q Disease causing (prob: 0.999) Probably damaging (0.984) Tolerated (0.29) 
p.C449R Disease causing (prob: 0.999) Probably damaging (1.000) Damaging (0) 
p.C456Y Disease causing (prob: 0.999) Probably damaging (1.000) Damaging (0) 
p.Y550* Disease causing (prob: 1) n/a n/a 
p.C1374R Disease causing (prob: 0.999) Probably damaging (0.999) Damaging (0) 
p.E1555* Disease causing (prob: 1) n/a n/a 
p.M1580Ifs*30 Disease causing (prob: 1) n/a n/a 
p.A1740S Polymorphism (prob: 0.980) Benign (0.134) Tolerated (0.42) 
p.S2017Tfs*9 Disease causing (prob: 1) n/a n/a 
 
 
1 
SUPPLEMENTAL FIGURE I.  Real-time PCR of transient transfections 
 
 
Real-time quantitative PCR of cells transiently transfected with mutagenized NOTCH1 cDNA constructs. All 
missense mutations tested demonstrate reduced NOTCH1 transcript level by comparison to cells transfected 
with a full-length wild-type construct (WT). Relative quantification of gene expression is calculated relative to 
the WT baseline value (set to 1) and normalized to GAPDH and ACTB. Graphs represent the mean of three 
independent experiments with error bars indicating SEM. Key: *p<0.01; †p<0.05 
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